AzTrials
AzTrials

mHealthNCT03231020

Parental Experience in the Single Ventricle Interstage Utilizing a mHealth Innovation: A Comparative Case Study

An observational study of mHealth and Adherence, Patient, run by Children's Mercy Hospital Kansas City at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to provide a rich description of the parental perspectives of utilizing a mHealth application for data transfer during the single ventricle interstage monitoring period. Read more about this study

Who is it for?
Any age
Conditions the study is for
mHealth, Adherence, Patient
What is being tested?
Interview
How many people
11 participants
Where
1 siteUnited States
Study dates
13 Sep 2019to 30 May 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Purposeful sampling will be used for recruiting among the first 80 infants from that used Cardiac High Acuity Monitoring Program (CHAMP) mHealth. All single and dual parent case sets will be recruited from a single tertiary center's pediatric cardiology department that used a mHealth application during the interstage period with the single ventricle team clinic known as CHAMP. Thus a case will be defined as the parent(s) of a single ventricle child who utilized CHAMP to monitor their baby at home during interstage with preliminary screening from the CHAMP Webportal through Children's Mercy Kansas City.

Who may be able to join

  • Adult over 18 years of age parent(s) of children with single ventricle cardiac disease
  • Parent(s) of children were discharge home in the interstage period from December 2013 to May 2017 that have completed the interstage period with Stage II Glenn cardiac surgery as of June 8th, 2017.
  • Parents(s) of children who were followed in the CHAMP clinic at Children's Mercy.
  • Parent(s) of CHAMP children who had the CHAMP mHealth application (CHAMP App) available for transfer of home monitoring data during the interstage

Who cannot join

  • Non-English speaking parent(s)
  • Parent(s) of children who were not discharged interstage

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children's Mercy Kansas City

    Kansas City, Missouri, 64108

Other trials in United States

About this study

The purpose of this study is to provide a rich description of the parental perspectives of utilizing a mHealth application for data transfer during the single ventricle interstage monitoring period. A gap in the body of knowledge of single ventricle cardiac disease interstage will be explored with these research questions: 1) How do parents of children (< 5 years of age) with single ventricle disease describe their experiences using a mHealth application during the interstage period (first 6-12 months of child's life)? And 2) How do these experiences influence their decision making for use of the mHealth application?

Read the detailed description

Background Nearly 2,000 infants with single ventricle cardiac disease are born each year in the United States, and have near certain mortality without surgical intervention. The heart with this congenital disease can never be converted to a four-chambered heart but rather, a palliative three-staged surgical strategy has been designed to maintain both circulation to the body and lungs without a pump. After an initial neonatal surgery, most infants are discharged home and return for a second surgery around six months of life. The time occurring between surgeries is known as the interstage period. This interstage period is very high risk and high demand time for parents, and there is a mortality rate during the interstage ranging from 2-20%, often from unknown reasons.

Hypoplastic left heart syndrome (HLHS) is a specific type of single ventricle disease that is one of the most complex forms of congenital heart disease. Publications have focused on improving the care of infants with HLHS using a Quality Improvement Model with the National Pediatric Cardiology Quality Improvement Collaborative (NPCQIC) through reduced variation, best practices, and transparency. The concept of interstage home monitoring to reduce mortality also was primarily focused on infants with only HLHS until recently when the focus was made onto comprehensive care from birth to 1 year of age. Hemodynamic data such as oxygen saturation, heart rate, intake, and overall status from a parental perspective were used to promote communication and attempts of early recognition of deterioration in this high-risk population. A strong set of qualitative studies have come from Rempel et al. in Canada on a cross-section of mainly white married parents of infants with HLHS and their parenting experience. Parenting under Pressure and the Facets of parenting a child with HLHS were studies which used the grounded theory approach and provided substantial additions to our knowledge of the interstage HLHS parenting experience. The basis of much of the care for all types of single ventricle cardiac disease at home is found from the care of HLHS and applied to infants with all types of single ventricle anatomy.

Most hospitals with pediatric cardiac surgery programs have interstage home monitoring programs for high risk infants with single ventricle heart disease to provide care and support for infants with all types of single ventricle cardiac disease. Education for caregivers of infants with single ventricle disease include guidelines to call health care providers (HCPs) in cases of hemodynamic interstage concerns, and symptom management questions, based on home monitoring of oxygen saturation and weight gain. There are variations in the staffing structure between pediatric hospitals but the programs often include care coordination and education by a nurse or advanced practice nurse communicating with parents in a reactive model waiting for data to be reported.

mHealth is defined through the National Institutes of Health (NIH) as the use of mobile and wireless devices to improve health outcomes, service, and research. The use of applications is widespread in adult care with estimated 40,000 health-care applications available. Some studies in pediatric medical homes have shown association of mHealth with adherence and self-monitoring to improved outcomes. mHealth innovations like the Cardiac High Acuity Monitoring Program (CHAMP) and other applications work most effectively when caregivers and interstage programs work together to improve care and are a focus of future research from the National Institute of Nursing Research. Much of the recent interstage literature focuses on mortality and weight measures with little focus on expanding types of outcomes to the parental and interstage teams' perspectives and phenomena like infant development.

Recent developments in technology can provide a proactive means for data transfer for home symptom monitoring so the interstage nursing team can review trends and provide proactive monitoring for infants in the interstage. Since 2012, two pilot studies have been published illustrating varying types of mHealth for the interstage with outcomes of improved somatic growth and an improved system of interstage data review but did not show significant mortality improvements. An innovative mHealth technology, CHAMP, was begun in 2014 for interstage home monitoring symptom management and found improved interstage mortality outcomes compared with historical controls. Research gaps remain in the role of adherence in this population to the mHealth technology and the parental experience of utilizing these innovative methods for communication with the clinical team.

Rationale The purpose of this study is to provide a rich description of the parental perspectives of utilizing a mHealth application for data transfer during the single ventricle interstage monitoring period for infants with congenital heart disease. The use of the case study design in healthcare has been encouraged by Robert Yin because it adapts to the complexity of interactions in a system that may be rapidly changing. Yin's qualitative case research "design propositions", presented below for this study, are applied to the literature and the PI's professional experience to focus the scope of the study and improve feasibility of completion of this qualitative case study approach research study. Propositions in this type of qualitative design are similar to hypothesis in quantitative designs to help formulate themes emerging from the data. The use of propositions may help with contributions for the body of knowledge after generalizing case study analysis, especially in cases of critical or extreme cases. Comparative analysis of the theoretical target (non-adherent parents) and rival cases (adherent parents) within the case study are improved with study propositions to guide the organization of data.

Study Propositions:

  1. The parental perspectives of the interstage period will influence the use of a home monitoring mHealth technology
  2. Parental perception of non-adherence of CHAMP and communication to the clinical team will match the actual non-adherence patterns of the mHealth innovation
  3. The use of Cardiac High Acuity Monitoring Program (CHAMP) application from the parental perspective will benefit future improvements in this technology
  4. Parents of infants with single ventricle will report the interstage report as a stressful time

Research Design

Methods. The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 "cases," each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period.

Yin defines various types of cases, including, explanatory or causal case studies, descriptive case studies, and exploratory case studies. The cases in this study are exploratory in that they focus on "what" can be learned from these cases of using a novel mHealth innovation and the CHAMP care team as a unit. Across the U.S., nearly 2,000 infants are born with single ventricle cardiac disease each year but the actual experience at home is difficult to comprehend. The research design is a multiple case study design with embedded units of non-adherent and adherent cases of parental use of CHAMP within the larger case group through the CHAMP Clinic at Children's Mercy Kansas City.

Data sources will include semi-structured interviews with parents that include observations of simulated home monitoring equipment and processes that had been previously used including location, time of day, and frequency.

Being tested
Interview
Keywords
single ventricle, pediatric cardiology, interstage, home monitoring, mHealth
Medical subject headings
Patient Compliance, Univentricular Heart

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • InterviewOther

    The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 "cases," each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period.

Study groups in NCT03231020
Study groupRoleWhat they receive
Adherent GroupParent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
Receives: Other: Interview
Non-Adherent GroupParent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
Receives: Other: Interview

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adherence to technology

    parental perspective on interstage period will influence the number of Data days during the interstage period

    Measured: 6 months

Secondary outcomes (2)
  1. Non-adherence to mHealth technology

    Parental perception of non-adherence of mHealth (CHAMP) and communication to the clinical team will match the actual non-adherence patterns of the mHealth innovation

    Measured: 6 months

  2. Parental Stress

    Parents of infants with single ventricle will report the interstage report as a stressful time

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2017
  2. Study start13 Sep 2019
  3. Primary completion26 Apr 2020
  4. Study completion30 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Prospective
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03231020
Sponsor's protocol ID
17050339
Status last verified
Jul 2020
First submitted
12 Jul 2017
Last updated
31 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Shirali G, Erickson L, Apperson J, Goggin K, Williams D, Reid K, Bradley-Ewing A, Tucker D, Bingler M, Spertus J, Rabbitt L, Stroup R. Harnessing Teams and Technology to Improve Outcomes in Infants With Single Ventricle. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):303-11. doi: 10.1161/CIRCOUTCOMES.115.002452. Epub 2016 May 10.

    PubMed 27166202
  • Yin RK. Enhancing the quality of case studies in health services research. Health Serv Res. 1999 Dec;34(5 Pt 2):1209-24.

    PubMed 10591280
  • Black AK, Sadanala UK, Mascio CE, Hornung CA, Keller BB. Challenges in implementing a pediatric cardiovascular home telehealth project. Telemed J E Health. 2014 Sep;20(9):858-67. doi: 10.1089/tmj.2013.0343. Epub 2014 Aug 1.

    PubMed 25083905
  • Rempel GR, Harrison MJ. Safeguarding precarious survival: parenting children who have life-threatening heart disease. Qual Health Res. 2007 Jul;17(6):824-37. doi: 10.1177/1049732307303164.

    PubMed 17582024

Questions about this trial

What is this clinical trial studying?

An observational study of mHealth and Adherence, Patient, run by Children's Mercy Hospital Kansas City at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adherence to technology (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03231020, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in